title: Reducing the rates of prescribing high-dose antipsychotics and polypharmacy on psychiatric inpatient and intensive care units: results of a 6-year quality improvement programme.
abstract: BACKGROUND
  There is no conclusive evidence that either high doses or combinations of antipsychotics are more effective than standard doses or monotherapy alone. Nonetheless, prescription of both remains prevalent in the UK. In 2006 the South London and Maudsley NHS Foundation Trust (SLAM) participated in a national survey of prescription of antipsychotic medications, organized by the Prescribing Observatory for Mental Health. Over half of the patients on SLAM inpatient or psychiatric intensive care units were prescribed a high-dose antipsychotic or a combination of antipsychotics. Prescribing high-dose antipsychotics and polypharmacy in SLAM was found to be among the highest in the UK.
  
  
  OBJECTIVE
  To assess the impact of a 6-year quality improvement programme aimed at reducing the rates of prescribing high-dose antipsychotics and polypharmacy on SLAM inpatients and psychiatric intensive care units.
  
  
  RESULTS
  There was a significant reduction between baseline and final survey in the rates of prescription of both high-dose antipsychotics and polypharmacy on SLAM inpatients and intensive care units (58% versus 10% p < 0.0001 and 57% versus 16%, p < 0.0001 respectively). The proportion of patients at final survey prescribed a high-dose antipsychotic and a combination was substantially lower in SLAM than in the national sample (10% versus 28%, p < 0.0001 and 16% versus 38%, p < 0.0001 respectively).
  
  
  CONCLUSIONS
  A sustained change in the prescribing culture of an organization can be achieved through a targeted improvement programme.
authors: Deputy Director of Pharmacy, South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK.
authors: Shubhra
authors: S
authors: Mace
authors: South London and Maudsley NHS Foundation Trust, London, UK.
authors: David
authors: D
authors: Taylor
keywords: antipsychotic; high dose; polypharmacy; prescribing; quality improvement
references: CNS Drugs. 2011 May;25(5):383-99
references: 21476610
references: Schizophr Res. 2007 Jan;89(1-3):91-100
references: 17070017
references: CNS Drugs. 2008;22(1):49-68; discussion 69-72
references: 18072814
references: Schizophr Bull. 2009 Mar;35(2):443-57
references: 18417466
references: Intern Med J. 2001 Dec;31(9):529-35
references: 11767867
references: Lancet. 2003 Oct 11;362(9391):1225-30
references: 14568747
references: Br J Psychiatry. 2005 Sep;187:243-7
references: 16135861
references: Arch Gen Psychiatry. 1988 Sep;45(9):789-96
references: 3046553
references: Clin Infect Dis. 2011 Oct;53(7):651-62
references: 21890770
references: Am J Psychiatry. 1997 Sep;154(9):1243-7
references: 9286183
references: CNS Drugs. 2009 Sep;23(9):773-80
references: 19689167
references: Arch Gen Psychiatry. 1988 Jan;45(1):79-91
references: 2892478
references: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003441
references: 17636723
references: Psychopharmacol Bull. 1996;32(4):683-97
references: 8993092
references: Br J Psychiatry. 1998 Oct;173:325-9
references: 9926037
references: Am J Psychiatry. 2011 Jul;168(7):702-8
references: 21536693
references: J Clin Psychopharmacol. 2008 Aug;28(4):392-400
references: 18626265
references: Psychol Med. 2008 May;38(5):705-15
references: 17825122
references: Acta Psychiatr Scand. 2006 Feb;113(2):135-41
references: 16423165
references: J Psychopharmacol. 2006 Jan;20(1):86-90
references: 16174679
references: Qual Saf Health Care. 2003 Jun;12(3):215-20
references: 12792013
references: Qual Saf Health Care. 2002 Jun;11(2):110-1
references: 12448794
references: Psychiatr Serv. 2004 Sep;55(9):1006-13
references: 15345760
references: BMJ. 1998 Aug 15;317(7156):465-8
references: 9703533
references: Int J Psychiatry Clin Pract. 2005;9(2):124-9
references: 24930794
references: Br J Psychiatry. 2008 Jun;192(6):435-9
references: 18515893
references: Aust N Z J Psychiatry. 2002 Oct;36(5):642-8
references: 12225448
references: Acta Psychiatr Scand. 2013 Mar;127(3):217-26
references: 22943577
references: Acta Psychiatr Scand. 2012 Jan;125(1):15-24
references: 22077319
references: Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25
references: 20459883
references: Am J Psychiatry. 2004 Apr;161(4):700-6
references: 15056517
references: Med Care. 2001 Aug;39(8 Suppl 2):II2-45
references: 11583120
references: J Psychopharmacol. 2013 Apr;27(4):327-36
references: 23413275